Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Last trade$1.00
Day change-$0.11 (-9.91%)
Day range$0.986 – $1.15
Volume4,077,297
Market cap$239M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$239.45M
Price / earnings
—
Price / book
0.84×
Price / sales
—
EV / sales
—
EV / EBITDA
0.22×
Profitability
Earnings per share
-$0.88
Return on assets
-56.32%
Return on equity
-66.75%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.06×
Current ratio
6.55×
Quick ratio
6.55×
Cash ratio
6.33×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$162.51M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CABA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$7.56M
$7.59M
$6.94M
$6.42M
$6.76M
$8.27M
$8.12M
$8.25M
Research and development
$47.14M
$44.43M
$37.35M
$36.19M
$39.82M
$37.64M
$29.02M
$25.53M
Total operating expenses
$54.71M
$52.11M
$43.96M
$42.61M
$46.59M
$45.97M
$37.14M
$33.79M
Operating income
-$54.71M
-$52.11M
-$43.96M
-$42.61M
-$46.59M
-$45.97M
-$37.14M
-$33.79M
Interest expense
-$511K
-$517K
-$636K
-$555K
-$584K
-$571K
-$294K
-$748K
Income before taxes
-$53.05M
-$51.02M
-$43.52M
-$41.92M
-$44.87M
-$45.13M
-$35.94M
-$32.59M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$53.05M
-$51.02M
-$43.52M
-$41.92M
-$44.87M
-$45.13M
-$35.94M
-$32.59M
Net income attributable to common shareholders
-$53.05M
-$51.02M
-$43.52M
-$41.92M
-$44.87M
-$45.13M
-$35.94M
-$32.54M
EBITDA
-$54.36M
-$51.73M
-$43.62M
-$42.26M
-$46.24M
-$45.5M
-$36.65M
-$33.32M
Basic earnings per share
-$0.28
-$0.34
-$0.39
-$0.40
-$0.44
-$0.73
-$0.71
-$0.65
Diluted earnings per share
-$0.28
-$0.34
-$0.39
-$0.40
-$0.44
-$0.73
-$0.71
-$0.65
Recent news
Company coverage with links to the original publishers.
The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8% CAGR through 2036, reaching significant expansion driven by rising disease awareness, improved diagnostics, and an expanding pipeline of targeted therapies. The market was valued at USD 714 million across the 7MM in 2025, with the US accounting for 55% of the market. Multiple pharmaceutical companies are advancing investigational treatments addressing unmet medical needs in dermatomyositis, polymyositis, and inclusion body myositis.
Cabaletta Bio announced positive Phase 1/2 clinical data for resecabtagene autoleucel (rese-cel), a CAR T cell therapy for autoimmune diseases. Results showed 100% of dermatomyositis patients maintained immunomodulator-free responses through one year, 100% of lupus nephritis patients achieved remission, and 71% of systemic sclerosis patients achieved improvement. The therapy demonstrated a favorable safety profile across 71 patients. Cabaletta anticipates topline results from the registrational dermatomyositis cohort in 2H27 and BLA submission in 1Q28.
The lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.
Cabaletta Bio announces positive clinical data for its rese-cel therapy in patients with myositis, lupus, and scleroderma, with most patients achieving clinically meaningful responses while off immunomodulators and steroids. The company plans to initiate registrational trials and engage with the FDA on regulatory pathways.
Cabaletta Bio announced plans to submit a Biologics License Application (BLA) for its rese-cel therapy in myositis by 2027, following recent alignment with the FDA on registrational cohorts for the RESET-Myositis trial. The company also received Regenerative Medicine Advanced Therapy (RMAT) designation for rese-cel in myositis.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.